Lentivirus and foamy virus vectors: novel gene therapy tools

被引:22
作者
Pandya, S
Klimatcheva, E
Planelles, V
机构
[1] Univ Rochester, Ctr Canc, Dept Med, Rochester, NY 14642 USA
[2] Univ Rochester, Ctr Canc, Dept Microbiol & Immunol, Rochester, NY 14642 USA
关键词
design of HIV-1 based vectors; foamy virus based vectors; lentiviral vectors; non-HIV-1 based vectors; safety issues in design of vectors;
D O I
10.1517/14712598.1.1.17
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The aim of gene therapy is to modify the genetic material of living cells to achieve therapeutic benefit. Gene therapy involves the insertion of a functional gene into a cell, to replace an absent or defective gene, or to fight an infectious agent or a tumour. At present, a wide variety of somatic tissues are being explored for the introduction of foreign genes with a view towards treatment. A prime requirement for successful gene therapy is the sustained expression of the therapeutic gene without any adverse effect on the recipient. A highly desirable vector would be generated at high titres, integrate into target cells (including non-dividing cells) and have little or no associated immune reactions. Lentiviruses have the ability to infect dividing and non-dividing cells and, therefore, constitute ideal candidates for development of vectors for gene therapy. This review presents a description of available lentiviral vectors, including vector design, applications to disease treatment and safety considerations. In addition, general aspects of the biology of lentiviruses with relevance to vector development will be discussed. Recent investigations have revealed that foamy viruses, another group of retroviruses, are also capable of infecting non-dividing cells. Thus, foamy virus vectors are actively being developed in parallel to lentivirus vectors. This review will also include various aspects of the biology of foamy viruses with relevance to vector development.
引用
收藏
页码:17 / 40
页数:24
相关论文
共 182 条
[2]   High-efficiency gene transfer into CD34(+) cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G [J].
Akkina, RK ;
Walton, RM ;
Chen, ML ;
Li, QX ;
Planelles, V ;
Chen, ISY .
JOURNAL OF VIROLOGY, 1996, 70 (04) :2581-2585
[3]   Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates [J].
Albright, AV ;
Shieh, JTC ;
Itoh, T ;
Lee, B ;
Pleasure, D ;
O'Connor, MJ ;
Doms, RW ;
González-Scarano, F .
JOURNAL OF VIROLOGY, 1999, 73 (01) :205-213
[4]   Biomedicine - Lentiviral vectors - the promise of gene therapy within reach? [J].
Amado, RG ;
Chen, ISY .
SCIENCE, 1999, 285 (5428) :674-676
[5]   Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: Expression and potential for helper virus-free packaging [J].
Arya, SK ;
Zamani, M ;
Kundra, P .
HUMAN GENE THERAPY, 1998, 9 (09) :1371-1380
[6]   INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS REACTIVATION FROM LATENCY BY A TAT TRANSDOMINANT NEGATIVE MUTANT [J].
BALBONI, PG ;
BOZZINI, R ;
ZUCCHINI, S ;
MARCONI, PC ;
GROSSI, MP ;
CAPUTO, A ;
MANSERVIGI, R ;
BARBANTIBRODANO, G .
JOURNAL OF MEDICAL VIROLOGY, 1993, 41 (04) :289-295
[7]   ANTISENSE PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES TARGETED TO THE VPR GENE INHIBIT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION IN PRIMARY HUMAN MACROPHAGES [J].
BALOTTA, C ;
LUSSO, P ;
CROWLEY, R ;
GALLO, RC ;
FRANCHINI, G .
JOURNAL OF VIROLOGY, 1993, 67 (07) :4409-4414
[8]  
Bell JE, 1998, REV NEUROL-FRANCE, V154, P816
[9]  
Belloc C, 1996, VET RES, V27, P395
[10]   THE ACTIVATION DOMAIN OF SIMIAN IMMUNODEFICIENCY VIRUS SIVMAC239 REV PROTEIN IS STRUCTURALLY AND FUNCTIONALLY ANALOGOUS TO THE HIV-1 REV ACTIVATION DOMAIN [J].
BERCHTOLD, S ;
HORNUNG, U ;
AEPINUS, C .
VIROLOGY, 1995, 211 (01) :290-295